Table 1.
CD4+ Effector (CD45RA+/CD27−) percent is an independent prognostic indicator in NSCLC
| Parameter | Low-risk group (low CD45RA+/CD27−%) | High-risk group (high CD45RA+/CD27−%) | P value |
|---|---|---|---|
| Survival (%) | 90.0 | 0.0 | 0.0000 |
| Median/maximum survival (days) | 2,343/2,447 | 516/1,751 | |
| Age (mean ± SD) | 63.8 ± 8.9 | 69.5 ± 8.0 | 0.16 |
| Gender (male/female) | 7/3 | 3/6 | 0.11 |
| Adenocarcinoma/squamous cell carcinoma | 10/0 | 5/4 | 0.02 |
| Stage (1/2/3/unknown) | 5/3/2/0 | 4/3/1/1 | 0.89 |
| Smoking Hx (current/former/never) | 2/6/2 | 3/4/2 | 0.76 |
| Surgery (segmentectomy/lobectomy/pneumonectomy/biopsy only) | 3/5/1/1 | 4/3/1/1 | 0.90 |
| Adjuvant chemo/rad (no/yes) | 5/5 | 6/3 | 0.46 |
| CD4/CD8 ratio (>1.27/≤1.27) | 3/7 | 6/3 | 0.11 |
| CD4+%naive (>0.65/≤0.65) | 7/3 | 3/6 | 0.11 |
Patients were stratified by BAL CD4+/CD45RA+/CD27− status (high or low) and demographic or clinical parameters were compared using the chi-square test in all cases, except for survival (log-rank test) and age (Student’s 2-tailed t test) comparisons. Samples with unknown stage were eliminated from the chi-square analysis of stage